SciSparc Ltd. (SPRC), a pharmaceutical company specializing in cannabinoid-based treatments, has received FDA approval to proceed with a Phase IIb clinical trial for its Tourette Syndrome (TS) medication, SCI-110. The trial will evaluate the drug’s efficacy, safety, and tolerability in adults, building upon promising results from earlier studies.